We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
BRAFTOVI Pierre Fabre Australia Pty Ltd
Product name
BRAFTOVI
Sponsor
Accepted date
Mar-2025
Active ingredients
encorafenib
Proposed indication
Braftovi (encorafenib) is an anti-cancer drug used to treat cancers that have a genetic change called a "BRAF V600E" mutation:
Braftovi (encorafenib) and binimetinib (another anti-cancer medication) are used together to treat adults with melanoma that cannot be removed by surgery or has spread to other parts of the body.
Braftovi (encorafenib) and cetuximab (another anti-cancer medication) are used together to treat adults with colorectal cancer that has spread to other parts of the body and who have already received other treatments.
Braftovi (encorafenib) and binimetinib are used together to treat adults with advanced non-small cell lung cancer.
Braftovi (encorafenib) and binimetinib (another anti-cancer medication) are used together to treat adults with melanoma that cannot be removed by surgery or has spread to other parts of the body.
Braftovi (encorafenib) and cetuximab (another anti-cancer medication) are used together to treat adults with colorectal cancer that has spread to other parts of the body and who have already received other treatments.
Braftovi (encorafenib) and binimetinib are used together to treat adults with advanced non-small cell lung cancer.
Application type
C (new indication)
Publication date
Mar-2025